Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio (Zyprexa). Excluding revenue from the olanzapine portfolio, total revenue increased 42%, and non-incretin revenue increased 17%.
Q3 2024 EPS increased to $1.07 on a reported basis and $1.18 on a non-GAAP basis, both inclusive of $3.
08 of acquired IPR&D charges. 2024 revenue guidance range updated to $45.4 to $46.
0 billion . 2024 reported EPS guidance updated to the range of $12.05 to $12.
55 , and non-GAAP EPS guidance updated to the range of $13.02 to $13.52 , both driven by the acquired IPR&D charges incurred in Q3.
Approvals included Ebglyss in the U.S. for moderate-to-severe atopic dermatitis and Kisunla in Japan for early symptomatic Alzheimer's disease.
Positive Phase 3 data included the 176-week study of tirzepatide showing 94% reduction in the risk of developing type 2 diabetes in adults with pre-diabetes, and obesity or overweight, and the six-month TRAILBLAZER-ALZ 6 trial showing that modified titration achieved similar levels of amyloid plaque removal while also reducing the incidence of ARIA-E to 14%, compared with 24% in the standard dosing regimen. INDIANAPOLIS , Oct. 30, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) today announced its financial results for the third quarter of 2024.
"Lilly had another strong growth quarter in Q3, with total revenue increasing .
